Protocol Ledger

NCT07759128 · Phase III · RECRUITING

A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder

Interventional Phase III clinical trial protocol NCT07759128 sponsored by Otsuka Pharmaceutical Development & Commercialization in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-07-28 Enrollment: 576 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07759128
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)576 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07759128
Protocol FieldVerified Registry Value
NCT IdentifierNCT07759128
Consolidated Lead SponsorOtsuka Pharmaceutical Development & Commercialization
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment576 participants (ESTIMATED)
Registered Start Date2026-07-28
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Otsuka Pharmaceutical across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI